3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Lung Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Urothelial Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
14
Nivolumab
13
Sunitinib
12
Axitinib
9
cabozantinib
8
belzutifan
8
Ipilimumab
7
Everolimus
5
atezolizumab
4
Sorafenib
4
temsirolimus
3
perifosine
3
motexafin gadolinium
3
Drug Therapy
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
lenvatinib
2
entinostat
2
ciforadenant
2
belinostat
2
avelumab
2
Paclitaxel
2
Immunotherapy
2
G250 monoclonal antibody
2
Fluorouracil
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Kidney Neoplasms
×
zimberelimab
×
Clear all
NCT05536141
2026-06-01
ARC-20
Arcus Biosciences, Inc.
Phase 1
Recruiting
362 enrolled